DocWire News Editors

DocwireNews

New research from the American Heart Association 2019 Scientific Sessions in Philadelphia suggest that different future trials are required to compare antiplatelets among transcatheter aortic valve replacement (TAVR) patients not requiring anticoagulation.
The Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes (GALILEO) trial was a  global, multicenter, open-label, randomized, event-driven, active-controlled phase III trial, researchers compared a rivaroxaban-based strategy versus an antiplatelet-based strategy after successful TAVR in 1,644 randomized patients who did have an ongoing indication for oral anticoagulation, such as atrial fibrillation, at the time of randomization.
The primary efficacy endpoint was the composite of all-cause death or thromboembolic events (including any stroke, myocardial infarction, symptomatic valve thrombosis, non-central nervous system systemic embolism, deep venous thrombosis or pulmonary embolism). The primary safety endpoint was the composite of major, disabling or life-threatening bleeding events according to the VARC-2 criteria.
The study results suggested that when comparing the two groups as formed in the very beginning, the rivaroxaban arm had higher rates of death or thromboembolic complications, and more bleeding complications. The trial was stopped early due to an increase in all-case mortality, and thromboembolic and bleeding events, in the rivaroxaban cohort. The researchers noted these high number of deaths could not be directly attributed to the higher bleeding rate observed the rivaroxaban arm.
Among patients randomized to rivaroxaban who died, a minority developed a significant bleeding event, heart attack or stroke 30 days prior to death. Most of the examined causes of death in the rivaroxaban arm were either sudden, occurred for unknown reasons, or were due to non-CV events. This left mechanism underlying the higher mortality in the rivaroxaban arm observed in the trial unclear, according to the researchers.
A discussant presentation noted that the implications of the study would first require awaiting the results of the TAVR population and noted that rivaroxaban 2.5 mg BID may be a reasonable dosage to study in future research.

Emily Menendez

Complete Response to Immunotherapy in HCC: Insights From IMbrave150

Hepatocellular Carcinoma

Anne Marie Morse, DO

Rob Dillard

Dr. Morse Talks About the Significance of World Sleep Day 2025

Sleep Disorders

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Latest News

GALILEO: Rivaroxaban-Based Antithrombotic Strategy or Antiplatelet-Based Strategy After TAVR?

AHA 2019

New research from the American Heart Association Scientific Sessions 2019 in Philadelphia suggest that different future trials are required to compare antiplatelets among ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe